A

gios Pharmaceuticals (AGIO) has already announced plans to seek U.S. approval for its second leukemia drug by the end of the year. On Wednesday, the biotech firm provided a peek at some of the clinical trial data that will support the new filing.

The Agios drug is called ivosidenib, and it works by blocking a mutated enzyme, IDH1, that is found in 6 to 10 percent of patients with acute myeloid leukemia (AML), a type of blood cancer that forms in the bone marrow and causes unchecked growth of abnormal white blood cells.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • So, if Agios is seeking end of the year filing ; is that breakthrough status ? If so, under the new FDARA Act, Race For Children , they are supposed to post expanded access policy and contact info. To allow a chance at life for those many not in their small, slow trials. Not that they shouldn’t already be doing the right moral thing , but that is lacking in PHRMA World…

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.